Physician profile
Ivan Benjamin Geller
NPI 1003923194
$505.66
in general payments reported to CMS, 2019-2025
10 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $198 · 2020: $97.16 · 2021: $211.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astellas Pharma US INC | $115.30 | 2020-2021 | |
| Teva Pharmaceuticals USA, INC. | $99.30 | 2019-2021 | |
| Avanir Pharmaceuticals, INC. | $72.41 | 2019 | |
| Abbvie INC. | $66.38 | 2019-2021 | |
| Allergan, INC. | $42.39 | 2019-2020 | |
| Alkermes, INC. | $31.20 | 2019-2020 | |
| Pfizer INC. | $26.22 | 2019 | |
| Sunovion Pharmaceuticals INC. | $19.63 | 2021 | |
| Novartis Pharmaceuticals Corporation | $18.67 | 2021 | |
| Neurocrine Biosciences, INC. | $14.16 | 2021 |
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Ivan Geller listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.